Published 2021
| Version v1
Publication
Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD
Additional details
Identifiers
- URL
- http://hdl.handle.net/11567/1045586
- URN
- urn:oai:iris.unige.it:11567/1045586
Origin repository
- Origin repository
- UNIGE